Addressing Safety Concerns with Biologic Therapies in IBD

This episode, titled “Addressing Safety Concerns with Biologic Therapies in IBD,” features panelists discussing the role of safety considerations, patient education, and long-term disease management in inflammatory bowel disease (IBD). Expert faculty explore common patient concerns surrounding biologic and advanced therapies, including fear of side effects and uncertainty regarding long-term treatment. The panel emphasizes the importance of balancing these concerns with the risks associated with uncontrolled inflammation and ongoing disease activity, including complications and extraintestinal manifestations such as joint pain and dermatologic conditions.

Throughout the discussion, expert faculty review how treatment selection is individualized based on the patient’s overall clinical picture, including comorbidities and symptoms beyond the gastrointestinal tract. The panel also highlights how therapies such as IL-23 inhibitors and JAK inhibitors may provide benefits across multiple inflammatory conditions. Using a patient case discussion, the patient panelist shares experiences with adverse dermatologic effects during prior therapy and describes how coordination between gastroenterology and dermatology specialists helped guide treatment decisions and optimize care.

In addition, the conversation reinforces the importance of ongoing monitoring and preventive care in patients receiving biologic therapies, including laboratory monitoring, vaccinations, dermatologic evaluations, and routine health maintenance. Expert faculty discuss how patient reassurance, education, and close follow-up can help reduce fear surrounding advanced therapies and improve confidence in treatment decisions. The panel concludes by emphasizing that the goals of modern IBD management extend beyond symptom control and focus on helping patients achieve a more normal quality of life through individualized, proactive care.

In the next episode, “Improving Quality of Life with Biologic Therapy in IBD,” panelists will discuss how biologic therapies can help patients achieve remission, regain confidence in daily activities, and improve long-term quality of life in IBD. The panel will also highlight the importance of treatment adherence, patient education, and early intervention in optimizing outcomes for patients living with inflammatory bowel disease.